Flow cytometric maturity score as a novel prognostic parameter in patients with acute myeloid leukemia

Tanja Schneider; Anne Flörcken; Anju Singh; Seval Türkmen; Thomas Burmeister; Ioannis Anagnostopoulos; Antonio Pezzutto; Bernd Dörken; Jörg Westermann

doi:10.1007/s00277-015-2400-5

Flow cytometric maturity score as a novel prognostic parameter in patients with acute myeloid leukemia

Standard

Flow cytometric maturity score as a novel prognostic parameter in patients with acute myeloid leukemia. / Schneider, Tanja; Flörcken, Anne; Singh, Anju; Türkmen, Seval; Burmeister, Thomas; Anagnostopoulos, Ioannis; Pezzutto, Antonio; Dörken, Bernd; Westermann, Jörg.

In: ANN HEMATOL, Vol. 94, No. 8, 08.2015, p. 1337-45.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Schneider, T, Flörcken, A, Singh, A, Türkmen, S, Burmeister, T, Anagnostopoulos, I, Pezzutto, A, Dörken, B & Westermann, J 2015, 'Flow cytometric maturity score as a novel prognostic parameter in patients with acute myeloid leukemia', ANN HEMATOL, vol. 94, no. 8, pp. 1337-45. https://doi.org/10.1007/s00277-015-2400-5

APA

Schneider, T., Flörcken, A., Singh, A., Türkmen, S., Burmeister, T., Anagnostopoulos, I., Pezzutto, A., Dörken, B., & Westermann, J. (2015). Flow cytometric maturity score as a novel prognostic parameter in patients with acute myeloid leukemia. ANN HEMATOL, 94(8), 1337-45. https://doi.org/10.1007/s00277-015-2400-5

Vancouver

Schneider T, Flörcken A, Singh A, Türkmen S, Burmeister T, Anagnostopoulos I et al. Flow cytometric maturity score as a novel prognostic parameter in patients with acute myeloid leukemia. ANN HEMATOL. 2015 Aug;94(8):1337-45. https://doi.org/10.1007/s00277-015-2400-5

Bibtex

@article{c082836f69f94bbab6915485dfb60102,

title = "Flow cytometric maturity score as a novel prognostic parameter in patients with acute myeloid leukemia",

abstract = "The European LeukemiaNet (ELN) classification is widely accepted for risk stratification of patients with acute myeloid leukemia (AML). In order to establish immunophenotypic features that predict prognosis, the expression of single AML blast cell antigens has been evaluated with partly conflicting results; however, the influence of immunophenotypic blast maturity is largely unknown. In our study, 300 AML patients diagnosed at our institution between January 2003 and April 2012 were analyzed. A flow cytometric maturity score was developed in order to distinguish {"}mature{"} AML (AML-ma) from {"}immature{"} AML (AML-im) by quantitative expression levels of early progenitor cell antigens (CD34, CD117, and TdT). AML-ma showed significantly longer relapse-free survival (RFS) and overall survival (OS) than AML-im (p < 0.001). Interestingly, statistically significant differences in RFS and OS were maintained within the {"}intermediate-risk{"} group according to ELN (RFS, 7.0 years (AML-ma) vs. 3.3 years (AML-im); p = 0.002; OS, 5.1 years (AML-ma) vs. 3.0 years (AML-im); p = 0.022). Our novel flow cytometric score easily determines AML blast maturity and can predict clinical outcome. It remains to be clarified whether these results simply reflect an accumulation of favorable molecular phenotypes in the AML-ma subgroup or whether they rely on biological differences such as a higher proportion of leukemia stem cells and/or a higher degree of genetic instability within the AML-im subgroup.",

keywords = "Adolescent, Adult, Aged, Aged, 80 and over, Female, Flow Cytometry, Humans, Leukemia, Myeloid, Acute, Male, Middle Aged, Neoplastic Stem Cells, Prognosis, Young Adult",

author = "Tanja Schneider and Anne Fl{\"o}rcken and Anju Singh and Seval T{\"u}rkmen and Thomas Burmeister and Ioannis Anagnostopoulos and Antonio Pezzutto and Bernd D{\"o}rken and J{\"o}rg Westermann",

year = "2015",

month = aug,

doi = "10.1007/s00277-015-2400-5",

language = "English",

volume = "94",

pages = "1337--45",

journal = "ANN HEMATOL",

issn = "0939-5555",

publisher = "Springer",

number = "8",

}

RIS

TY - JOUR

T1 - Flow cytometric maturity score as a novel prognostic parameter in patients with acute myeloid leukemia

AU - Schneider, Tanja

AU - Flörcken, Anne

AU - Singh, Anju

AU - Türkmen, Seval

AU - Burmeister, Thomas

AU - Anagnostopoulos, Ioannis

AU - Pezzutto, Antonio

AU - Dörken, Bernd

AU - Westermann, Jörg

PY - 2015/8

Y1 - 2015/8

N2 - The European LeukemiaNet (ELN) classification is widely accepted for risk stratification of patients with acute myeloid leukemia (AML). In order to establish immunophenotypic features that predict prognosis, the expression of single AML blast cell antigens has been evaluated with partly conflicting results; however, the influence of immunophenotypic blast maturity is largely unknown. In our study, 300 AML patients diagnosed at our institution between January 2003 and April 2012 were analyzed. A flow cytometric maturity score was developed in order to distinguish "mature" AML (AML-ma) from "immature" AML (AML-im) by quantitative expression levels of early progenitor cell antigens (CD34, CD117, and TdT). AML-ma showed significantly longer relapse-free survival (RFS) and overall survival (OS) than AML-im (p < 0.001). Interestingly, statistically significant differences in RFS and OS were maintained within the "intermediate-risk" group according to ELN (RFS, 7.0 years (AML-ma) vs. 3.3 years (AML-im); p = 0.002; OS, 5.1 years (AML-ma) vs. 3.0 years (AML-im); p = 0.022). Our novel flow cytometric score easily determines AML blast maturity and can predict clinical outcome. It remains to be clarified whether these results simply reflect an accumulation of favorable molecular phenotypes in the AML-ma subgroup or whether they rely on biological differences such as a higher proportion of leukemia stem cells and/or a higher degree of genetic instability within the AML-im subgroup.

AB - The European LeukemiaNet (ELN) classification is widely accepted for risk stratification of patients with acute myeloid leukemia (AML). In order to establish immunophenotypic features that predict prognosis, the expression of single AML blast cell antigens has been evaluated with partly conflicting results; however, the influence of immunophenotypic blast maturity is largely unknown. In our study, 300 AML patients diagnosed at our institution between January 2003 and April 2012 were analyzed. A flow cytometric maturity score was developed in order to distinguish "mature" AML (AML-ma) from "immature" AML (AML-im) by quantitative expression levels of early progenitor cell antigens (CD34, CD117, and TdT). AML-ma showed significantly longer relapse-free survival (RFS) and overall survival (OS) than AML-im (p < 0.001). Interestingly, statistically significant differences in RFS and OS were maintained within the "intermediate-risk" group according to ELN (RFS, 7.0 years (AML-ma) vs. 3.3 years (AML-im); p = 0.002; OS, 5.1 years (AML-ma) vs. 3.0 years (AML-im); p = 0.022). Our novel flow cytometric score easily determines AML blast maturity and can predict clinical outcome. It remains to be clarified whether these results simply reflect an accumulation of favorable molecular phenotypes in the AML-ma subgroup or whether they rely on biological differences such as a higher proportion of leukemia stem cells and/or a higher degree of genetic instability within the AML-im subgroup.

KW - Adolescent

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Female

KW - Flow Cytometry

KW - Humans

KW - Leukemia, Myeloid, Acute

KW - Male

KW - Middle Aged

KW - Neoplastic Stem Cells

KW - Prognosis

KW - Young Adult

U2 - 10.1007/s00277-015-2400-5

DO - 10.1007/s00277-015-2400-5

M3 - SCORING: Journal article

C2 - 25994787

VL - 94

SP - 1337

EP - 1345

JO - ANN HEMATOL

JF - ANN HEMATOL

SN - 0939-5555

IS - 8

ER -